Clinical trials: Head and Neck Cancer
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Esophageal Squamous Cell Carcinoma
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants…
- Trial name
- NCT05319730
- Testing
- Paclitaxel, Irinotecan, Pembrolizumab
- Where
- 58 sites in United States, Brazil and 12 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent and/or Metastatic Head and Neck Cancer
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or recurrent squamous cell carcinoma of the head…
- Trial name
- SPECTRUM (NCT00460265)
- Testing
- ARM 2, ARM 1
- Volunteers
- 658 people
- Sponsor
- Amgen
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
Head and Neck Neoplasms
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Study Objectives: To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00268671
- Testing
- Docetaxel
- Volunteers
- 45 people
- Sponsor
- Sanofi
Esophageal Cancer
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
This is an open-label, multicenter, phase Ib study to evaluate the safety, tolerability, and preliminary efficacy of AN0025 in combination with chemoradiotherapy (CRT) in patients with locally advanced/locally recurrent…
- Trial name
- NCT05191667
- Testing
- AN0025
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Breast Neoplasm, Head and Neck Neoplasm
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C.
- Conditions
- Breast Neoplasm, Head and Neck Neoplasm, Skin Neoplasm, Respiratory Tract Neoplasm
- Trial name
- Tenatumomab (NCT02602067)
- Testing
- 131I-Tenatumomab
- Where
- 7 sites in France, Italy
- Volunteers
- 2 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Esophageal Squamous Cell Carcinoma
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced…
- Trial name
- KUNLUN (NCT04550260)
- Testing
- Durvalumab, cisplatin + fluorouracil, cisplatin + capecitabine
- Where
- 133 sites in United States, Belgium and 14 more
- Volunteers
- 640 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Head and Neck Cancer
Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
This is a German, observational study in adult participants diagnosed with squamous cell carcinoma of the head and neck (SCCHN) progressing on or after platinum-based therapy, who start a new systemic therapy with nivolumab in…
- Trial name
- NCT03114163
- Where
- Germany
- Volunteers
- 485 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumours, Non-Small Cell Lung Cancer
First in Human Study of SIM0610 in Solid Tumors
This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of SIM0610 in subjects with locally…
- Conditions
- Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- SIM0610-101 (NCT07348211)
- Testing
- SIM0610 for Injection
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Head, Neck and Chest Cancer
A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
AK105 is a humanized monoclonal antibody that specially binds to PD-1. Anlotinib is a small molecule tyrosine kinase inhibitor. Based on the mechanism study, tumor vascular abnormalities promote tissue hypoxia and increase lactic…
- Trial name
- NCT04203719
- Testing
- AK105, Anlotinib
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumors
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
- Trial name
- FORTITUDE-301 (NCT05325866)
- Testing
- Bemarituzumab
- Where
- 115 sites in United States, Argentina and 24 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Melanoma (Skin), Squamous Cell Carcinoma of the Skin
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.
- Conditions
- Melanoma (Skin), Squamous Cell Carcinoma of the Skin, Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Adenoid Cystic
- Trial name
- NCT03291002
- Testing
- CV8102, CV8102 + anti-PD-1 therapy
- Where
- 22 sites in Austria, France and 3 more
- Volunteers
- 98 people
- Sponsor
- CureVac
Advanced Solid Tumors Cancer
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and…
- Trial name
- NCT04196283
- Testing
- ABBV-368, Tilsotolimod, Nab-paclitaxel
- Where
- 26 sites in United States, France and 4 more
- Volunteers
- 30 people
- Sponsor
- AbbVie
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with…
- Trial name
- NCT05342636
- Testing
- Pembrolizumab, Coformulation favezelimab/pembrolizumab, MK-4830
- Where
- 46 sites in Brazil, Chile and 11 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT04843098
- Testing
- TL117, Paclitaxel
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Suzhou Junde Biotechnology Co., Ltd
Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with…
- Conditions
- Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Breast
- Trial name
- NCT02565758
- Testing
- ABBV-085
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- AbbVie
Head and Neck Neoplasms
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced…
- Trial name
- NCT00357149
- Testing
- Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy, Concomitant cisplatin, 5-FU and radiotherapy
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.